Pharmacological prevention of post-ERCP pancreatitis: The facts and the fiction

Journal of the Pancreas

Volumn 5, Issue 4, 2004, Pages 171-178

  Testoni, Pier Alberto ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

Acute disease; Botulinum toxins; Chemicals and drugs category; Cytokines; Gabexate; Pancreatitis; Primary prevention; Protease inhibitors; Serine proteinase inhibitors

Indexed keywords

ADRENALIN; ALLOPURINOL; BOTULINUM TOXIN; COMPLEMENT COMPONENT C1S INHIBITOR; DICLOFENAC; GABEXATE; GABEXATE MESILATE; GLYCERYL TRINITRATE; HEPARIN; LIDOCAINE; NIFEDIPINE; OCTREOTIDE; PROTEINASE INHIBITOR; RECOMBINANT INTERLEUKIN 10; SECRETIN; SOMATOSTATIN;

ACUTE PANCREATITIS; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; EDITORIAL; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; HIGH RISK POPULATION; HUMAN; HYPERTENSION; INCIDENCE; NONHUMAN; ODDI SPHINCTER; PANCREAS DUCT LIGATION; POSTOPERATIVE CARE; RISK ASSESSMENT; RISK FACTOR; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; ANIMAL; CHEMOPROPHYLAXIS; PANCREATITIS;

ANIMALS; CHEMOPREVENTION; CHOLANGIOPANCREATOGRAPHY, ENDOSCOPIC RETROGRADE; HUMANS; PANCREATITIS;

EID: 6344248930     PISSN: 15908577     EISSN: 15908577     Source Type: Journal    
DOI: None     Document Type: Editorial

References (35)

1. Freeman ML. Post-ERCP pancreatitis: patient- and technique-related risk factors. JOP. J. Pancreas (Online) 2002; 3:169-76.
2. Rabenstein T, Hahn EG. Post-ERCP pancreatitis: is the endoscopist's experience the major risk factor? JOP. J Pancreas (Online) 2002; 3:177-87.
3. Rashdan A, Fogel EL, McHenry L Jr, Sherman S, Temkit M, Lehman GA. Improved stent characteristics for prophylaxis of post-ERCP pancreatitis. Clin Gastroenterol Hepatol 2004; 2:322-9.
4. Raty S, Sand J, Pulkkinen M, Matikainen M, Nordback I. Post-ERCP pancreatitis: reduction by routine antibiotics. J Gastrointest Surg 2001; 5:339-45.
5. Deviere J, Le Moine O, Van Laethem JL, Eisendrath P, Ghilain A, Severs N, Cohard M. Interleukin-10 reduces the incidence of pancreatitis after therapeutic endoscopic retrograde cholangiopancreatography. Gastroenterology 2001; 120:498-505.
6. Sudhindran S, Bromwich E, Edwards PR. Prospective randomized double-blind placebo-controlled trial of glyceryl trinitrate in endoscopic retrograde cholangiopancreatography-induced pancreatitis. Br J Surg 2001; 88:1178-82.
7. Rabenstein T, Roggenbuck S, Framke B, Martus P, Fischer B, Nusko G, et al. Complications of endoscopic sphincterotomy: can heparin prevent acute pancreatitis after ERCP? Gastrointest Endosc 2002; 55:476-83.
8. Moreto M, Zaballa M, Casado I, Merino O, Rueda M, Ramirez K, et al. Transdermal glyceryl trinitrate for prevention of post-ERCP pancreatitis: a randomized double-blind trial. Gastrointest Endosc 2003; 57:1-7.
9. Murray B, Carter R, Imrie C, Evans S, O'Suilleabhain C. Diclofenac reduces the incidence of acute pancreatitis after endoscopic retrograde cholangiopancreatography. Gastroenterology 2003; 124:1786-91.
10. Poon RT, Yeung C, Liu CL, Lam CM, Yuen WK, Lo CM, et al. Intravenous bolus somatostatin after diagnostic cholangiopancreatography reduces the incidence of pancreatitis associated with therapeutic endoscopic retrograde cholangiopancreatography procedures: a randomized controlled trial. Gut 2003; 52:1768-73.
11. Masci E, Cavallini G, Mariani A, Frulloni L, Testoni PA, Curioni S, et al. Comparison of two dosing regimens of gabexate in the prophylaxis of post-ERCP pancreatitis. Am J Gastroenterol 2003; 98:2182-6.
12. Jowell PS, Branch S, Robuck-Mangum G, Fein S, Purich ED, et al. Synthetic Secretin administered at the start of the procedure significantly reduces the risk of post-ERCP pancreatitis: a randomized, double-blind, placebo controlled trial. [Abstract]. Gastroenterology 2003; 125:605.
13. Arvanitidis D, Anagnostopoulos GK, Giannopoulos D, Pantes A, Agaritsi R, Margantinis G, et al. Can somatostatin prevent post-ERCP pancreatitis? Results of a randomized controlled trial. J Gastroenterol Hepatol 2004; 19:278-82.
14. Gorelick A, Barnett J, Chey W, Anderson M, Elta G. Botulinum toxin injection after biliary sphincterotomy. Endoscopy 2004; 36:170-3.
15. Andriulli A, Leandro G, Niro G, Mangia A, Festa V, Gambassi G, et al. Pharmacological treatment can prevent pancreatic injury after ERCP: a meta-analysis. Gastrointest Endosc 2000; 51:1-7.
16. Andriulli A, Clemente R, Solmi L, Terruzzi V, Suriani R, Sigillito A, et al. Gabexate or somatostatin administration before ERCP in patients at high risk for post-ERCP pancreatitis: a multicenter, placebo-controlled, randomized clinical trial. Gastrointest Endosc 2002; 56:488-95.
17. Andriulli A, Solmi L, Loperfido S, Festa V, Belmonte A, Leo P, et al. Somatostatin (SST) and gabexate (GM) are ineffective in preventing post-ERCP complications. [Abstract]. Gastrointest Endosc 2004; 59:AB106.
18. Lung E. The use of somatostatin or octreotide to prevent post-ERCP pancreatitis: a meta-analysis of randomized, controlled trials. [Abstract]. Gastrointest Endosc 2004; 59:AB107.
19. Testoni PA, Cicardi M, Bergamaschini L, Guzzoni S, Cugno M, Buizza M, et al. Infusion of C1-inhibitor plasma concentrate prevents hyperamylasemia induced by endoscopic sphincterotomy. Gastrointest Endosc 1995; 42:301-5.
20. Cavallini G, Tittobello A, Frulloni L, Masci E, Mariana A, Di Francesco V. Gabexate for the prevention of pancreatic damage related to endoscopic retrograde cholangiopancreatography. N Engl J Med 1996; 335:919-23.
21. Dumot JA, Conwell DL, Zuccaro G Jr, Vargo JJ, Shay SS, Easley KA, Ponsky JL. A randomized, double blind study of interleukin 10 for the prevention of ERCP-induced pancreatitis. Am J Gastroenterol 2001; 96:2098-102.
22. Budzynska A, Marek T, Nowak A, Kaczor R, Nowakowska-Dulawa E, A prospective randomized, placebo-controlled trial of prednisone and allopurinol in the prevention of ERCP-induced pancreatitis. Endoscopy 2001; 33:766-72.
23. Manolakopoulos S, Avgerinos A, Vlachogiannakos J, Armonis A, Viazis N, Papadimitriou N, et al. Octreotide versus hydrocortisone versus placebo in the prevention of post-ERCP pancreatitis: a multicenter randomized controlled trial. Gastrointest Endosc 2002; 55:470-5.
24. Sherman S, Blaut U, Watkins JL, Barnett J, Freeman M, Geenen J, et al. Does prophylactic administration of corticosteroids reduce the risk and severity of post-ERCP pancreatitis: a randomized, prospective, multicenter study. Gastrointest Endosc 2003; 58:23-9.
25. Rabenstein T, Fischer B, Wiessner V, Schmidt H, Radespiel-Troger M, Hochberger J, et al. Low-molecular-weight heparin does not prevent acute post-ERCP pancreatitis. Gastrointest Endosc 2004; 59:606-13.
26. Ohashi A, Tamada K, Tomiyama T, Wada S, Higashizawa T, Gotoh Y, et al. Epinefrine irrigation for the prevention of pancreatic damage after endoscopic balloon sphincteroplasty. J Gastroenterol Hepatol 2001; 16:568-71.
27. Prat F, Amaris J, Ducot B, Bocquentin M, Fritsch J, Choury AD, et al. Nifedipine for prevention of post-ERCP pancreatitis: a prospective, double-blind randomized study. Gastrointest Endosc 2002; 56:202-8.
28. Schwartz JJ, Lew RJ, Ahmad NA, Shah JN, Ginsberg GG, Kochman ML, et al. The effect of lidocaine sprayed on the major duodenal papilla on the frequency of post-ERCP pancreatitis. Gastrointest Endosc 2004; 59:179-84.
29. Gottlieb K, Sherman S. ERCP and endoscopic biliary sphincterotomy-induced pancreatitis. Gastrointest Clin N Am 1998; 8:87-114.
30. Loperfido S, Angelini G, Benedetti G, Chilovi F, Costan F, De Berardinis F, et al. Major early complications from diagnostic and therapeutic ERCP: a prospective multicenter study. Gastrointest Endosc 1998; 48:1-10.
31. Masci E, Toti G, Mariani A, Curioni S, Lomazzi A, Dinelli M, et al. Complications of diagnostic and therapeutic ERCP: a prospective multicenter study. Am J Gastroenterol 2001; 96:417-23.
32. Sherman S, Ruffolo TA, Hawes RH, Lehman GA. Complications of endoscopic sphincterotomy: a prospective study with emphasis on the increased risk associated with sphincter of Oddi dysfunction and nondilated bile ducts. Gastroenterology 1991; 101:1068-75.
33. Sherman S, Hawes RH, Rathgaber SW, Uzer MF, Smith MT, Khusro QE, et al. Post-ERCP pancreatitis: randomized, prospective study comparing a low- and high-osmolality contrast agent. Gastrointest Endosc 1994; 40:422-7.
34. Freeman ML, Nelson DB, Sherman S, Haber GB, Herman ME, Dorsher PJ, et al. Complications of endoscopic biliary sphincterotomy. N Engl J Med 1996; 335:909-18.
35. Pasha TM, Therneau T, Petersen BT. Economic analysis of gabexate mesilate in post-ERCP pancreatitis. [Abstract]. Gastroenterology 1997; 112:A471.